Table 1. Baseline patient and tumor characteristics.
| Characteristics | Schedule A n = 16 (% of total) |
Schedule B n = 46 (% of total) |
|---|---|---|
| Gender | ||
| Male/Female | 9 (56)/7 (44) | 28 (61)/18 (39) |
| Median age (range) | 55 (48–69) | 61 (43–74) |
| ECOG Performance status | ||
| 0 | 8 (50) | 22 (48) |
| 1/2 | 7 (44)/ 1 (6) | 13 (50)/1 (2) |
| Clinical staging | ||
| T3N0 | 3 (19) | 1 (2) |
| T3N1/T4N0 | 7 (44)/1 (6) | 14 (30)/1 (2) |
| T3N2/T4N1-2 | 2 (12)/2 (12) | 22 (48)/1 (2) |
| T3N0M1/T3N1M1 | – | 1 (2)/2 (4) |
| T3N2M1/T4N2M1 | 1 (6)/0 | 3 (7)/1 (2) |
| Distance from the anal verge | ||
| ≤5 cm (low-lying tumor) | 9 (56) | 25 (54) |
| >5 cm (mid/upper tumor) | 7 (44) | 21 (46) |
| Distance of Mesorectal Fascia (MRF) | ||
| ≤5 mm | 13 (81) | 35 (76) |
| >5 mm | 2 (12) | 8 (18) |
| Not evaluated* | 1 (6) | 3 (7) |
| Baseline CEA serum level | ||
| ≤5 UI/L | 10 (62) | 28(61) |
| >5 UI/L | 6 (37) | 18 (39) |
*
MRI not performed, metal prosthesis.